Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These gastrointestinal adverse events are poorly documented in the literature due to their low frequency [6].”
From Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis (2025) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial gastrointestinal side effects were reported by approximately 30% of participants, which were generally mild to moderate in severity and significantly diminished during sustained treatment achieved through dose titration, resulting in a discontinuation rate of less than 8% [87].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These are more likely to occur within the first weeks of initiation of therapy and with dose escalation. Side effects tend to decrease in frequency and severity with continuation of a stable dose [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Higher doses are more likely to provoke these adverse symptoms, indicating a dose‐dependent relationship [40].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because dietary lipids act synergistically with GLP-1 to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [66]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global clinical measure of fitness and frailty in elderly people
Rockwood, K. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050051 · Cited by 8,968 · cited 1×
“The Clinical Frailty Scale may sometimes be useful to guide dose adjustment [75].”
MethodLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“CKD increases the risk of GLP-1 RA-associated diarrhoea, with symptoms being more severe with albuminuria [84].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“Although reported data from trials and real-world series do not show definitive differences between GLP-1 RAs in terms of tolerability (Table 1), there are studies claiming that the tolerability profile may vary between differe t compounds [1,33,39].”
BackgroundResultSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Of note, a recent meta-analysis encompassing those clinical trials focused on the cardiovascular safety of GLP-1 RAs found significant reductions in MACE3 (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), hospitalization for heart failure and progression of chronic kidney di…”
ResultDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566 · cited 1×
“Sarcopenia risk must be assessed before and during GLP-1 RA treatment since the sharp weight loss in the elderly may be in part at the expense of lean mass [80,81].”
Background
Research works printed but not linked: 2
- 2010, Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients’ selection from a multidisciplinary approach, Av. Diabetol., 26, 226
- 2014, Pancreatitis aguda severa y precoz por liraglutide, Arch. Med. Int., 36, 119
Cited by
Items 201–300 of 355
GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care
Șufaru, I.-G., Vasiliu, B. C., Hăncianu, M., Stratul, Ş., Tatarciuc, M., Iovan, G., Tatarciuc, D., Rudnic, I., Hanu, D., Paduraru, S., et al. (2026) · Biomolecules · doi:10.3390/biom16060857 · Cited by 6
“Medication management in periodontal care should therefore emphasize structured history-taking, interdisciplinary communication, and prevention of avoidable complications during active therapy and maintenance [171].”
Wan, K., Lei, E. F., Liu, Y., Taddese, A. A., Ip, P. C. T., Torbahn, G., Weghuber, D., Huang, W. Y., & Tam, B. T. (2026) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2026.2248 · Cited by 7
Chuang, Y.-S., Wright, J. D., Wong, M.-T., Paneliya, K. J., Yang, W., Chu, H., Chang, T. W., & Polasek, T. M. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70224 · Cited by 2
Cote, M. F., Oza, V. S., & Orlow, S. J. (2026) · Pediatric Dermatology · doi:10.1111/pde.70340 · Cited by 2
Barrientos-Ávalos, J. R., Morel-Cerda, E. C., Téllez, F. A. F., Vidrio-Huerta, B. E., Aceves-Ayala, A. R., Flores-Rendón, Á. R., & Velasco, J. A. V.-R. (2024) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2024.07.001 · Cited by 7
Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report
Hvisdas, C., Goode, N., Kim, D. H., Silvey, M. J., & Flood, J. J. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.117 · Cited by 2
Kamarullah, W., Pranata, R., Wiramihardja, S., & Tiksnadi, B. B. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00695-9 · Cited by 3
Great Weight, Low Pressure–One Problem: GLP-1 Receptor Agonist-Associated Colonic Ischemia
Ramrakhiani, H., Roorda, A. K., Tran, T., Shetler, K. P., & Triadafilopoulos, G. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08984-2 · Cited by 2
Chau, H. C., Liu, J. Y. H., & Rudd, J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-95961-4 · Cited by 2
Airosus, C., Ardabili, N. G., Hyde, A., & Davidson, T. L. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.114955 · Cited by 2
Gut microbiome alterations in type 2 diabetes following COVID-19: A comprehensive review
Bose, N., Bisht, D., Kumar, M. V., Nawar, K. A., Chalissery, B., Neha, D., Dung, N. D., Rawat, S., Ahuja, D., Choudhary, R. K., et al. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100643 · Cited by 3
Michelet, A., Mowla, M., Amo-Brown, B. A., Rodriguez, N., & Cavaretta, M. J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251372054 · Cited by 4
Dutta, D., Chatterjee, S., Datta, P. K., Mohindra, R., & Sharma, M. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_162_23 · Cited by 1
“[20] Hence, there still remains the need for urgent RCTs comparing the glycaemic efficacy and durability of PEG‑Lox (100 mcg/ week and 200 mcg/week) with those of other established antidiabetes medications like peer GLP1RAs, sodium‑glucose contransporters‑2 (SGLT2) inhibitors, sulfonylureas, and…”
BackgroundVázquez, L. A., Tofé, S., Bellido, D., Botella-Serrano, M., Soto-González, A., Mezquita‐Raya, P., Delgado, E., Fajardo, C., Morales, C., Causanilles, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01587-6 · Cited by 2
Self-citationManagement of Obesity in Bangladesh – Position Statement of Bangladesh Endocrine Society
Haq, T., Robel, M. A. B., Kobra, T., Karim, M. R., Ahammed, A., Mahjabeen, S., Sarkar, S., Tanni, A. Z., Hossain, T., Mustari, M., et al. (2024) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_35_24 · Cited by 2
Unmasking Gastroparesis in Diabetes During Ramadan: Challenges and Management Strategies
Abdulrasak, M., Shaat, N., Someili, A. M., & Mohrag, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061997 · Cited by 2
“If gastroparesis symptoms exist, a dose reduction in GLP-1 analog may be considered, with a focus on patient-specific factors, including risk for hyperglycemia and the potential for using pro-motility agents to ameliorate GLP-1 analog-related delayed GE [89].”
Suzuki, R., Chand, K., & Taguchi, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01739-2 · Cited by 2
“In real-world clinical practice, some patients may experience gastrointestinal adverse events (AEs) with oral semaglutide, which may impact treatment adherence [17].”
Pu, J., Huang, Y., Wan, L., Zhu, M., Wei, H., Gao, H., Zhong, L., Tang, C., & Xu, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16610 · Cited by 2
“Gastrointestinal reactions represent the most common AEs associated with GLP-1R targeted medications, 11 – 13 which generally occur during the first weeks of treatment and decline over time.”
Alpert, Z., Katzman, J. L., Lajam, C. M., Schwarzkopf, R. M., & Rozell, J. C. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.08.068 · Cited by 2
Singhal, R., Sachdeva, D., Wortman, K., II, & Lall, R. (2025) · Cureus · doi:10.7759/cureus.91679 · Cited by 12
“Clinically, this case underscores the necessity of strict adherence to semaglutide titration protocols, such as restarting at 0.25 mg per week and escalating slowly, to minimize gastrointestinal adverse effects [16].”
InfluentialJia, W., Jiang, F., Xu, Y., Li, Y., Bao, Y., & WANG, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70112 · Cited by 1
“32,33 This pattern mirrors SUSTAIN and SURPASS trial data and supports tolerability.”
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Palmer, R. C., Telang, S. S., Kistler, N. M., Mayfield, C. K., Hong, K. M., Gucev, G., Lieberman, J. R., & Heckmann, N. D. (2025) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-025-04604-x · Cited by 2
“Patients in the dose-escalation phase are more likely to experience pronounced suppression of gastric emptying and gastrointestinal side effects due to drug naïvety [31 , 32 ].”
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
“The overall safety profile of tirzepatide and semaglutide is favorable and consistent with other incretin-based therapies, with gastrointestinal (GI) symptoms representing the most common adverse events [62].”
Malhotra, D., Henderson, J., Turner, C. D., O’Rourke, R. W., McAuley, K. B., Heisler, M., Otto, M. G., Thomason, C., O’Neill, J. L., Freeman, K., et al. (2026) · Primary Health Care Research & Development · doi:10.1017/s1463423625100650 · Cited by 1
Zhu, Z.-N., You, C., Yuan, Q., Xu, J.-Y., Gu, Z.-Y., Huang, Z., Liu, M., Shan, B., Wang, J. J., Hu, W., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01720-6 · Cited by 2
“Yet these groundbreaking therapies reveal both the promise and limitations of current approaches: while validating GPCRs as metabolic drug targets, they are constrained by gastro-intestinal side effects, injection-based delivery, prohibitive costs, and variable patient responses [8].”
Li, Z., Wang, X., He, Y., Hu, K., Liu, Y., Zhang, W., Ma, Y., & Jiang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1754925 · Cited by 2
Chang, L., Hassan, S., Chasse, J., Stern, G. M., Gabovitch, D., Zelle, D., Colling, C., Crossen, J., Aronson, S., Oates, M., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107359 · Cited by 1
Sibutramine high-doses effects in cafeteria diet-induced obese rats
Ribeiro, F. M., Lima, H. K., Ribeiro, C. F. A., Silva, O. N., Mendonça, G., de Oliveira, N. C., Pereira, R. W., de Castro, A., & Franco, O. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-35214-0 · Cited by 1
“A spontaneous decline in energy intake was observed between weeks 12 and 16, particularly in the cafeteria diet groups.”
Self-citationFarkas, G. J., Solinsky, R. J., & Park, A. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.02.498 · Cited by 1
Eiswirth, E., & Salib-Barrios, M. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105766 · Cited by 1
Alhamdan, Y. R., Hsu, J. C., & Lu, C. Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70718 · Cited by 1
“Gastrointestinal adverse effects are among the most frequent reasons for GLP-1 receptor agonist dose modification or discontinuation in both trials and real-world settings [9, 15, 16].”
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
Obesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Saeed, Z. I., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.006 · Cited by 1
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
“In contrast, GLP-1 receptor agonists and next-generation incretin co-agonists exert broader systemic metabolic effects, including weight loss, improvement of insulin resistance, reduction in systemic inflammation, and favorable modulation of cardiometabolic risk [103–105].”
Sancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists
Idowu, T. O., & Chmurzyńska, A. (2026) · Journal of Applied Genetics · doi:10.1007/s13353-026-01084-5 · Cited by 1
Varma, G., Murugadoss, K., Kurian, M. E., Varghese, J., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag035 · Cited by 3
“These findings are consistent with known challenges in GLP-1RA therapy but provide direct, large-scale evidence from clinical documentation [14, 15, 27].”
Ahmed, M. M., Nazari, R., Othman, Z. K., Musa, S. S., Okesanya, O. J., Adebayo, U. O., Branda, F., Elmi, A. H., & Prisno, D. E. L. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261472587 · Cited by 2
Castaneda, R., Sepulveda-Gonzalez, D., Andrade, M. D. H., SHUFELT, C. L., & Faubion, S. S. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002854 · Cited by 3
Maslin, K., Shawe, J., Blowers, S., Ceulemans, M., Hart, K. H., Schoenmakers, S., Rottenstreich, A., Hopper, H., Jensterle, M., Flynn, A. C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70203 · Cited by 3
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2714267 · Cited by 1
“A multidisciplinary consensus panel [57] provided guidance on avoiding or minimizing symptoms (nausea, vomiting, gas-troesophageal reflux, diarrhea, constipation).”
Narla, S., & Narla, R. R. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.07.030 · Cited by 1
Yabe, D., Shiraiwa, T., Ugai, H., Takeuchi, M., & Suzuki, R. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00138-5 · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“During treatment initiation or dose escalation, smaller meals, slower eating, reduced meal fat load, and avoidance of very large portions may improve tolerability and adherence [124].”
Al‐Majmuei, A., Alatoom, M., Abdullahi, F., Marza, L., Murjan, N. A., Qasmi, R. A., Al-Rahbi, T., AlOmar, H., Alsherooqi, R., & Arekat, D. Z. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02671-7 · Cited by 1
Au, K., & Yang, W. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07061-3 · Cited by 1
“%) of AEs in people with obesity treated with GLP-1 RAs were not severe [4].”
Renna, N. F., Zaidel, E. J., Corral, P., & Lerner, A. (2024) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2024.07.006 · Cited by 1
Liraglutide - A Promising Approach Against Obesity
Rafi, N., Jaffri, M. S. A., & Yousuf, K. (2025) · Journal of Bahria University Medical and Dental College · doi:10.51985/jbumdc2024-455
Hanna, C., Comstock, F., Chatrath, S., Posner, A. R., Butsch, J. L., Blum, K., Gold, M. S., Georger, L. A., Mastrandrea, L. D., Quattrin, T., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1516122 · Cited by 1
Astapenko, O. O., & Rozhnov, A. (2025) · SUCHASNA STOMATOLOHIYA · doi:10.33295/1992-576x-2025-4-112 · Cited by 1
Messiah, S. E., Ernest, D. K., Cruz-Munoz, N. F. D. L., Lipshultz, S. E., & Barlow, S. E. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114616 · Cited by 1
Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique
Scheen, A. J. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.05.006
Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States
Boye, K. S., Jordan, J. B., Malik, R., & Matza, L. S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01499-x
“Dose escalation is commonly required during the early phases of treatment with oral and injectable T2D therapies, such as metformin, liraglutide, tirzepatide, dulaglutide, and semaglutide [24–26].”
BackgroundMedication Use in Older Adults With Type 2 Diabetes
Inteso, C. (2024) · ADCES in Practice · doi:10.1177/2633559x241256105
Initiating non-insulin-based treatment in adults with type 2 diabetes: a practical guide
Stewart, M. (2024) · Primary Health Care · doi:10.7748/phc.2024.e1828
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
Moore, K. T., Gupta, A. S., Shen, J., & Kumar, P. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6136
“18 Nausea was the most frequently reported adverse event, with a frequency of 5% to 59% across the different compounds, irrespective of the respective half-life or route of administration.”
Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa
Bueno, E., Jara-Ruiz, E., Jara, J., Arce, M., Ramírez, A. I., & Canata, G. (2024) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2024.057.03.102 · Cited by 2
Mazur, M., Waz, D., Szarłowicz, J., Goliszek, Z., Sobek, K. Ł., Tabin-Barczak, W., Sokołowska, A., Fikas, K., Chwaliszewski, K., & Samuła, S. (2024) · Quality in Sport · doi:10.12775/qs.2024.36.56722
Medically Supervised Weight Loss and Effects of Anti-Obesity Medications
Sheer, A. J., Donahoo, W. T., & Johnson-Mann, C. N. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_14
Challenges and Novelties in the Treatment of Obesity in Adults. A review
Kuczapska, K., Kurowski, M., Gliwa, A., Ryglewicz, M., Fabian, D., Leszczyńska-Knaga, E., Jakubczyk, N., Rutkowska-Kawalec, W., Moczydłowski, P., & Michalczuk, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.57095
Alhamedi, N. M. (2025) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2025.6104 · Cited by 1
“In patients with Type 2 Diabetes (T2D), GLP-1 receptor agonists-an injectable class of anti-diabetic medications — enhance glycemic control and improve several atherosclerosis-related markers [2].”
GLP-1RA: New Hope in Obesity Therapy
Zhang, D., & Lu, H. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.132035
“Initiating treatment with a low dose and titrating up based on patient tolerance can help minimize adverse reactions [66].”
The science behind the lifesum app: an intervention design analysis
Svanfeldt, S., Seth, C., Gners, M., & Blomqvist, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-97852-0
“Furthermore, since there are fewer calories consumed 77 , understanding what healthy food is in order to meet the demands of the body 78 .”
HbA1c reduction strategies: An overview of pharmacological interventions
Upadhye, K. S., Patidar, H., Bamnia, N., & Yadav, N. K. (2025) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_72_24 · Cited by 2
Exploring the off-label use of liraglutide in the treatment of obesity: a review
Braga, C. B. A., Segundo, J. P. V. A., & Filho, C. A. A. D. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05560-8 · Cited by 1
“Adverse effects of liraglutide have also been discussed as contributing to reduced appetite and weight loss [22, 23].”
Miller, C. K., Young-Hyman, D. L., Wooldridge, J. S., Piatt, G., & Hawkins, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0020 · Cited by 1
Barlowe, T. S., Gouker, L. N., Buse, J. B., Sandler, R. S., & Dougherty, M. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-025-00472-w
Minnetti, M., Piciocchi, C., Frigerio, F., Vincenzo, O. D., Muzzioli, L., Poggiogalle, E., Migliaccio, S., & Donini, L. M. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01653-6
The physiologic and psychologic effects of glucagon-like peptide-1 receptor agonists
Bradwisch, S. A., Smith, E. M., Wilson-Mooney, C., & Donahue-Stathis, C. (2025) · Nursing · doi:10.1097/nsg.0000000000000223 · Cited by 1
Refaeli, R., Green, G., Boaz, M., Dotan, I., Raziel, A., Peffer-Gik, T., Buch, A., & Dagan, S. S. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01887-2 · Cited by 2
“Table 3 summarizes recommendations for managing the most common GI side effects of incretin-based OMMs as arises by the HCPs and literature review [21, 26, 28, 38 – 54].”
InfluentialPrajapati, P., Shafi, N., Pachchipulusu, V., Fatima, N., Noorien, S., Biswas, S. K., Narula, A., Aishwarya, K., Prajapati, S. D., Patel, M. K., et al. (2025) · medRxiv · doi:10.1101/2025.09.01.25334855
Empowering Pharmacists in Heartburn Management: Practical Insights for OTC Treatment and Self-Care
Bridgeman, M. B., Hospattankar, A. V., Siddiqui, K., & Nakhla, N. R. (2025) · Pharmacy · doi:10.3390/pharmacy13050124 · Cited by 1
“…the treatment of type 2 diabetes mellitus (T2DM) and obesity, may be associated with gastrointestinal side effects including nausea, delayed gastric emptying, and heartburn, [12–15] stemming from their impact on delaying gastric motility and increasing gastric acid exposure in the esophagus [12].”
Incretins for obesity: closer to a nicotine patch than a silver bullet
Dippel, I., Adelman, M., Olson, K. M., Holt, A., Collins, J., Reddest, A., & Carris, N. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2557458
“Individuals experiencing nausea can avoid eating within 30 minutes of an incretin dose, avoid overpowering smells, and eat foods the individual finds easy on the stomach [83].”
InfluentialWang, Y., Xiao, Q.-Z., Zhang, Z., & Yang, Y. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i9.110639
Kodela, M. P., Sasi, N. O. A., & Rao, R. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i9.2037
Integrating DL in Breast Cancer Detection: A Study on DNN and GAN Models for Early Detection
Oggu, K., Jain, Y., Vadlani, S. N., & Thota, H. R. (2025) · Lecture notes in networks and systems · doi:10.1007/978-981-96-8639-1_12
Yuce, T. K., Radwan, R. M., Lee, Y. A., Holler, E., Dai, H., He, X., Huang, Y., Guo, Y. M., Bian, J., & Guo, J. S. (2025) · medRxiv · doi:10.1101/2025.11.21.25340747
“25 Furthermore, our findings of comparable rates of complications associated with MSB, including bowel obstruction, internal hernia, and gastrointestinal hemorrhage, between groups further support the safe use of GLP-1 RA in this patient population.”
Essverhalten nach bariatrischer Operation oder unter GLP-1/GIP-Therapie
Thaden, S. (2025) · Ernährung & Medizin · doi:10.1055/a-2533-8246
“Häufige Nebenwirkungen bei diesen Wirkstoffen betreffen vor allem den Gastrointesti - naltrakt (z. B. Übelkeit, Erbrechen, Diarrhö) [6].”
Phan, V., Bethune, B., & Lathrop, B. L. (2025) · Nursing for Women s Health · doi:10.1016/j.nwh.2025.09.003
Obezite Tedavisinde Güncel Yaklaşımlar
Coşkun, M., & DUMAN, A. (2025) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub1126.c4585
Deng, C.-X., Chen, Z.-M., Tang, Y.-X., Xi, Z.-X., Wang, S.-Y., Wu, H.-Y., Xu, B., & Xu, T.-C. (2026) · World Journal of Pharmacology · doi:10.5497/wjp.v15.i1.113080
Sikorska, L. M., Liu, V. N., Johnson, H., Chaudry, E., Reisel, D., Clift, A. K., & Huang, D. R. (2026) · Cureus · doi:10.7759/cureus.102817 · Cited by 1
“There is an emerging consensus within the field that GIP/GLP-1 RA should be used together with comprehensive care, including behavioural and dietary support, to maximise the benefits and minimise the risks of treatment [11].”
High fat diet remodels the gene regulatory networks in the preoptic area
Lazaro, O., Beimfohr, C., App, B., Basu, R., Johnson, T. S., & Flak, J. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-37692-8
Abdulraheem, A., Abujaber, B. A., Ayers, L., Afzal, U., Qarkash, D., Altork, N. A., Zureikat, Q. A., Bashiri, K., Almhanni, G., Peppas, S., et al. (2026) · Clinical Endoscopy · doi:10.5946/ce.2025.137
Katzman, J. L., Alpert, Z., Kennedy, M., Rozell, J. C., Schwarzkopf, R. M., & Lajam, C. M. (2026) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-025-06167-2
Diaz, M. E. C., Kim, G., & Vakharia, M. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156317
Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Preshy, A., Fernandez, C. J., Nedai, M. H., & Pappachan, J. M. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70040
“Incretin‐based agents commonly cause gastrointestinal toxicity, including nausea, vomiting, delayed gastric emptying, diarrhea and constipation in approximately 40%–70% patients and are the leading cause for impaired adherence [69].”
2025 Nutrition Science & Communications Forum: Summary
Steiber, A. L., Paulsen, E., & Brown, N. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156324
Semaglutide as a potential tool in pre–lung transplant weight loss optimization
Ali, R., Keyt, H., Solis‐Herrera, C., & Escobar-Vasco, M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag040
“Further research thereafter suggested that while GLP1-RAs may delay gastric emptying, response is variable and that the actual risk of worsening reflux, aspiration, and subsequent aspiration pneumonia has not been identified [23-26].”
Efficacy of glucocorticoid modulator PT150 as a weight loss strategyPreprint
Glass, V. M., McDougle, M. J., Smith, W., Dhillon, P. S., Ha, L., Ledo, J. H., Verrico, C. D., & Azevedo, E. P. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.712688
Sammut, M. J., Thorne, B. R., Saeed, L., McBey, D. P., & Melling, C. W. J. (2026) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000004014
Hong, K. M., SULO, S. S., Wang, W., Kim, M., Hong, L., Kerr, K. W., Fan, L., & Williams, D. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s574765 · Cited by 1
“12 Addressing this gap is critical, especially as these therapies expand in use across diverse populations.”
Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?
Meulman, G., Foran, A., & Roberts, D. M. (2026) · Internal Medicine Journal · doi:10.1111/imj.70458
Kamrul-Hasan, A. B. M., Khalil, I., Mahajan, K., Dutta, D., Banerjee, M., & Pappachan, J. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70247
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731
“It is recommended that at least 30 minutes have passed since the most recent GLP-1 RA dose before patients may consume foods that help alleviate nausea [83].”
Parekh, R. S., Inban, P., Thai, A., Agrawal, A., Kudaiarov, D., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102150
Metadata
- Authors
- Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á.
- Affiliations
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
- Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain
- Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain
- Hospital Universitario La Paz (ES)
- Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain
- Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain
- Hospital Clínico Universitario de Valencia (ES)
- Madrid Health Service (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Universitat de València (ES)
- Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain
- Corresponding author
- Górriz, José Luis
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-12-24
- Volume
- 12
- Issue
- 1
- Pages
- 145
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9821052
- OpenAlex
- W4313260808
- Cited by
- 358
- References
- 83
- Citations by year
- 2026: 137 · 2025: 140 · 2024: 63 · 2023: 18
- FWCI
- 40.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
- Funders
- Novo-Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, type 2 diabetes, obesity, dose escalation, maintenance dose, treatment discontinuation, glycemic control, weight loss, patient education
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.